Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The event will take place on Monday, January 13, 2025, at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. Management will present a company overview and engage in a Q&A session. During the presentation, Alnylam will discuss its unaudited fourth quarter and full year 2024 global net product revenues.
A live audio webcast of the presentation and Q&A session will be accessible on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be made available on the website within 48 hours post-event.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader nelle terapie RNAi, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare.
L'evento si terrà
lunedì 13 gennaio 2025, alle 9:45 am PT (12:45 pm ET) presso il The Westin St. Francis di San Francisco. La direzione presenterà una panoramica dell'azienda e parteciperà a una sessione di domande e risposte. Durante la presentazione, Alnylam discuterà le sue entrate globali netti da prodotti non verificati per il quarto trimestre e per l'intero anno 2024.
Una diretta audio della presentazione e della sessione di domande e risposte sarà accessibile nella sezione Investitori del sito web dell'azienda, www.alnylam.com/events. Una registrazione sarà disponibile sul sito entro 48 ore dopo l'evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un líder en terapias de RNAi, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare.
El evento tendrá lugar el lunes 13 de enero de 2025, a las 9:45 am PT (12:45 pm ET) en The Westin St. Francis en San Francisco. La dirección presentará una visión general de la empresa y participará en una sesión de preguntas y respuestas. Durante la presentación, Alnylam discutirá sus ingresos netos globales de productos no auditados para el cuarto trimestre y el año completo 2024.
Una transmisión en vivo de audio de la presentación y la sesión de preguntas y respuestas estará disponible en la sección de Inversores del sitio web de la empresa, www.alnylam.com/events. Se pondrá disponible una repetición en el sitio dentro de las 48 horas posteriores al evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY), RNAi 치료의 선두주자가 제43회 J.P. Morgan Healthcare 컨퍼런스에 참여한다고 발표했습니다.
이 행사는 2025년 1월 13일 월요일, 오전 9시 45분 PT (오후 12시 45분 ET) 샌프란시스코의 The Westin St. Francis에서 열릴 예정입니다. 경영진은 회사 개요를 발표하고 Q&A 세션에 참여할 것입니다. 발표 중 Alnylam은 2024년 4분기 및 전체 연도에 대한 감사되지 않은 글로벌 순 제품 수익에 대해 논의할 것입니다.
발표와 Q&A 세션의 라이브 오디오 웹캐스트는 회사 웹사이트의 투자자 섹션에서 접근 가능하며, www.alnylam.com/events를 방문하시면 됩니다. 이벤트 후 48시간 이내에 사이트에 다시 보기 기능이 제공됩니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader des thérapies par ARNinterférent, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare.
L'événement se déroulera le lundi 13 janvier 2025, à 9h45 PT (12h45 ET) au The Westin St. Francis à San Francisco. La direction présentera un aperçu de l'entreprise et participera à une session de questions-réponses. Lors de la présentation, Alnylam discutera de ses revenus nets mondiaux de produits non audités pour le quatrième trimestre et l'année entière 2024.
Un webinaire audio en direct de la présentation et de la session de questions-réponses sera accessible dans la section des Investisseurs du site Web de l'entreprise, www.alnylam.com/events. Un enregistrement sera disponible sur le site dans les 48 heures suivant l'événement.
Alnylam Pharmaceuticals (Nasdaq: ALNY), ein führendes Unternehmen im Bereich RNAi-Therapien, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben.
Die Veranstaltung findet am Montag, den 13. Januar 2025, um 9:45 Uhr PT (12:45 Uhr ET) im The Westin St. Francis in San Francisco statt. Das Management wird eine Unternehmensübersicht präsentieren und an einer Q&A-Session teilnehmen. Während der Präsentation wird Alnylam über die nicht geprüften globalen Nettoprodukterlöse für das vierte Quartal und das Gesamtjahr 2024 sprechen.
Ein Live-Audio-Webcast der Präsentation und der Q&A-Session wird im Investorenbereich der Unternehmenswebsite verfügbar sein, www.alnylam.com/events. Eine Wiederholung wird innerhalb von 48 Stunden nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106988056/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When will Alnylam present at the 43rd Annual J.P. Morgan Healthcare Conference?
What will Alnylam discuss during the J.P. Morgan Healthcare Conference?
Where can I watch Alnylam's presentation at the J.P. Morgan Healthcare Conference?
Will there be a replay of Alnylam's presentation at the J.P. Morgan Healthcare Conference?
What time is Alnylam's Q&A session at the J.P. Morgan Healthcare Conference?
What are the key highlights expected from Alnylam's presentation at the J.P. Morgan Healthcare Conference?
